Navigation Links
Ipsen in Medical News

Dysport Available! New Wrinkle Treatment in Washington, DC Offers Botox Alternative

...d from the bacterium Clostridium Botulinum. Dysport has been available in Europe, Asia and South America for over 10 years. Dysport is manufactured by ipsen Pharmaceuticals (FRA) and distributed in the United States by Medicis, manufacturer of the Restylane dermal filler . Many cosmetic physicians o...

Merzenich Elected to Institute of Medicine

... his seminal and ongoing research into the "plasticity" or "malleability" of adult brains. He has been honored with many other awards, including the ipsen Prize, Zulch Prize, Thomas Alva Edison Award, Purkinje Medal, and Karl Spencer Lashley Award. Dr. Merzenich has published more than 200 scientific art...

Galderma Completes Tender Offer for CollaGenex

...R), Cetaphil(R) and Epiduo(R) are trademarks of Galderma Pharma S.A. Pliaglis(R) is a trademark of Zars Pharma Inc. and Dysport(R) is a trademark of ipsen Ltd. All other trade names, trademarks or service marks are the property of their respective owners and are not the property of CollaGenex Pharmaceu...

QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes

... SA ADS (Nasdaq: FLML ) Hospira Inc. (NYSE: HSP ) Human Genome Sciences, Inc. (Nasdaq: HGSI ) Indevus Pharmaceuticals Inc. (Nasdaq: IDEV ) ipsen Ltd. (Paris: IPN.PR) Nastech Pharmaceutical Co. (Nasdaq: NSTK ) Nektar Therapeutics (Nasdaq: NKTR ) NicOx S.A. (Paris: NCOX) OSI Pharmaceuti...

Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals

...R), Cetaphil(R) and Epiduo(R) are trademarks of Galderma Pharma S.A. Pliaglis(R) is a trademark of Zars Pharma Inc. and Dysport(R) is a trademark of ipsen Ltd. All other trade names, trademarks or service marks are the property of their respective owners and are not the property of CollaGenex Pharmaceu...

Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM)

..., Cetaphil(R) and Epiduo(R) are trademarks of Galderma Pharma S.A. Pliaglis(TM) is a trademark of ZARS Pharma, Inc. and Dysport(R) is a trademark of ipsen Ltd. ...

Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals

...), Cetaphil(R) and Epiduo(R) are trademarks of Galderma Pharma S.A. Pliaglis(TM) is a trademark of Zars Pharma Inc. and Dysport(R) is a trademark of ipsen Ltd. All other trade names, trademarks or service marks are the property of their respective owners and are not the property of CollaGenex Pharmaceu...

Ipsen and Debiopharm Extend Their Agreement for the Exclusive Commercialization of Decapeptyl(R) (triptorelin pamoate) in Europe and Certain Other Territories

...nnounced the extension of their agreement, whereby ipsen exclusively in-licenses know-how and new patent ap...eted formulations in July 2010. It further enables ipsen to access future sustained-release formulations of...nd is expected to be filed by Debiopharm in 2008. ipsen will thus be able to propose Decapeptyl(R) in a wi...

Omnicom Acquires Leading Healthcare Marketing Communications Firm in China

...trategic consulting, marketing research, marketing communications and advertising. Consultech's clients include Novartis, Novo Nordisk, Xian- Janssen, ipsen and China Resources Corp. "Through Consultech joining Omnicom, we have strengthened our ability to deliver a full scope of services to our healthcare...
Ipsen in Medical Technology

Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration

PARIS--(BUSINESS WIRE)--Jun 11, 2007 - Regulatory News-Ipsen (Paris:IPN) announced today that the preliminary data from the ongoing phase III study for its investigational 4-month formulation of triptorelin do not support the expected sustainable blood levels of triptorelin for a duration of 4 mont...

Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl(R) to Further Help Prostate Cancer Patients

... or metastatic, hormone-dependent prostate cancer. Once approved, Decapeptyl(R) 6-month formulation will be marketed by Debiopharm's partners, such as ipsen in most European Union countries. "This submission in Europe of our first 6-month-formulation for the treatment of prostate cancer is another demons...

Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials

...the role of GLP-1 in type 2 diabetes and Roche and ipsen believe taspoglutide has the potential to be a bes...he and Jean-Luc Belingard, Chairman and CEO of the ipsen Group. "GLP-1 analogues, which stimulate insulin s... true innovations in the diabetes field. Roche and ipsen are pleased to move this potentially best-in-class...
Ipsen in Biological News

Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action

...-inflammatory therapies. FXT is managed by a very experienced team and is financed by Index Ventures and Novo A/S, while its shareholders also include ipsen and Cambridge University. FXT has research and office facilities in Cambridge. For more information about FXT, please visit our web site ( www.funxio...
Ipsen in Biological Technology

Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action

...-inflammatory therapies. FXT is managed by a very experienced team and is financed by Index Ventures and Novo A/S, while its shareholders also include ipsen and Cambridge University . FXT has research and office facilities in Cambridge. For more information about FXT, please visit our web site ( ht...

New Report Just Published: World Prostate Cancer Therapeutics Market Report

...ent Technology II-82 Misonix Expands HIFU Business in Europe by Entering into Spain II-82 Altana Divests Entire Stake in GPC Biotech II-83 ipsen Enters into Partnership with GTx to Develop and Market Acapodene in Europe II-83 Egenix and Proteome Systems Collaborate to Develop Prostate ...

Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer

...on, Mr. Bansal was chief financial officer and executive vice president of corporate and business development for Tercica, Inc., which was acquired by ipsen in 2008. From February 2003 to January 2006, he was chief financial officer of Nektar Therapeutics. From July 2002 until joining Nektar, Mr. Bansal ...

Brain and Hearing Pioneer, Michael Merzenich, Ph.D. to Speak at Case Western Reserve University

... to overcome cognitive challenges." Dr. Merzenich was recently elected to the Institute of Medicine and has received awards and prizes including the ipsen Prize, Zulch Prize of the Max Planck Institute, Thomas Alva Edison Patent Award and Purkinje Medal. A founder of many companies such as Scientific Lea...

Galderma Completes Acquisition of CollaGenex

... Novacort and Alcortin A are trademarks of Primus Pharmaceuticals, Inc. Pliaglis is a trademark of Zars Pharma Inc. Dysport is a trademark of ipsen Ltd. All other trade names, trademarks or service marks are the property of their respective owners. ...

QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes (As Revised)

...gies SA ADS (Nasdaq: FLML ) Hospira Inc. (NYSE: HSP ) Human Genome Sciences, Inc. (Nasdaq: HGSI ) Indevus Pharmaceuticals Inc. (Nasdaq: IDEV ) ipsen Ltd. (Paris: IPN.PR) Nektar Therapeutics (Nasdaq: NKTR ) NicOx S.A. (Paris: NCOX) OSI Pharmaceuticals Inc. (Nasdaq: OSIP ) ProStrakan Group Plc ...

YM BIOSCIENCES NOTICE OF ANNUAL MEETING OF SHAREHOLDERS AND NOMINATION OF DIRECTORS

...a. He was previously Vice President Licensing, Medical Affairs and Pharmacogenomics at Genset (Paris, France), Vice President, Clinical Development at ipsen (Paris, France) and Assistant Professor of Medical Oncology at Institut Gustave Roussy (Paris, France). Four of the current directors, Dr. James Barr...

Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis

... together could total more than $500 million, part of which will be paid to ipsen (Euronext: FR0010259150; IPN), from which Radius licensed BA058 in 2005. In...g Japan) to develop, manufacture, and distribute BA058 and its analogs from ipsen in 2005. About Radius (http://www.radiuspharm.com ) Radius is a leading ...
Other Tags
(Date:7/28/2014)... (HealthDay News) -- People with higher levels of brown ... a new study suggests. Unlike white fat, which ... improves insulin sensitivity, blood sugar control and fat-burning metabolism. ... people," Labros Sidossis, a professor of internal medicine in ... Texas Medical Branch at Galveston, said in a ...
(Date:7/28/2014)... (SMU) Smart phones and mobile devices are on ... health ("mHealth") apps capable of providing everything from cardiac ... broaden access to medical treatment and control costs, several ... England Journal of Medicine (NEJM) report that more ... Administration (FDA) to ensure consumer confidence and safety. Out ...
(Date:7/28/2014)... 2014 The website, which is hosted ... industry, went live in January 2014. The honor recognizes ... of excellence that comprise the web’s most professional work. ... , “What pleases me the most is that we ... categories,” said Joshua Snow, web manager, Abington Health. “We ...
(Date:7/28/2014)... Ridgeland, MS (PRWEB) July 28, 2014 ... recently announced the graduates of its Advanced Training ... students, who fill roles in their health care ... the theory and methodology of continuous quality improvement ... a sister-program to Dr. Brent James’ internationally recognized ...
(Date:7/28/2014)... 2014: ESC Congress 2014 promises to be bigger, better ... Fox, Chair of the Congress Programme Committee. The European ... influential cardiovascular event every year in August. Record numbers ... year and the congress is on track to host ... , Asked why an extra hot line session has ...
Breaking Medicine News(10 mins):Health News:Healthy 'Brown Fat' May Cut Odds for Obesity, Diabetes 2Health News:Booming mobile health app market needs more FDA oversight for consumer safety, confidence 2Health News:Abington Health Website Named Best in Class 2Health News:HORNE LLP’s Healthcare Delivery Institute Graduates Class from the Advanced Training Program 2Health News:ESC Congress 2014 focuses on innovations in cardiology 2Health News:ESC Congress 2014 focuses on innovations in cardiology 3
(Date:7/27/2014)... new in vitro study has revealed that nicotine and ... damage caused by a certain carcinogen in smoke. , ... curing of tobacco leaves and ultimately ends up in ... the lung and liver, where it is activated by ... research in mice has revealed that nicotine can partially ...
(Date:7/27/2014)... date, researchers from the U.K. provide national, regional, and ... (HCV). Findings published in Hepatology, a journal of the ... that genotype 1 is the most prevalent worldwide, with ... in East Asia. Genotype 3, at just over 54 ... genotypes 2, 4, 6, and 5. , Despite ...
(Date:7/27/2014)... can evade treatment by acquiring mutations in the genes ... were once thought to be the only way for ... shown that microorganisms can use a temporary silencing of ... the benefits of drug resistance without the commitment. , ... called Mucor circinelloides, it is likely to be employed ...
Breaking Biology News(10 mins):Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2Hepatitis C virus genotype 1 is most prevalent worldwide 2Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3
Other Contents